Potential therapeutic agents against COVID-19: What we know so far.
Identifieur interne : 001A33 ( Main/Corpus ); précédent : 001A32; suivant : 001A34Potential therapeutic agents against COVID-19: What we know so far.
Auteurs : Chih-Chia Lu ; Mei-Yu Chen ; Wan-Shin Lee ; Yuh-Lih ChangSource :
- Journal of the Chinese Medical Association : JCMA [ 1728-7731 ] ; 2020.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (drug therapy), Drug Combinations (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Interferon-alpha (therapeutic use), Lopinavir (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Hydroxychloroquine, Interferon-alpha, Lopinavir, Ritonavir.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Clinical Trials as Topic, Drug Combinations, Humans, Pandemics, SARS-CoV-2.
Abstract
The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
DOI: 10.1097/JCMA.0000000000000318
PubMed: 32243270
PubMed Central: PMC7176266
Links to Exploration step
pubmed:32243270Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential therapeutic agents against COVID-19: What we know so far.</title><author><name sortKey="Lu, Chih Chia" sort="Lu, Chih Chia" uniqKey="Lu C" first="Chih-Chia" last="Lu">Chih-Chia Lu</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Mei Yu" sort="Chen, Mei Yu" uniqKey="Chen M" first="Mei-Yu" last="Chen">Mei-Yu Chen</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Wan Shin" sort="Lee, Wan Shin" uniqKey="Lee W" first="Wan-Shin" last="Lee">Wan-Shin Lee</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, Yuh Lih" sort="Chang, Yuh Lih" uniqKey="Chang Y" first="Yuh-Lih" last="Chang">Yuh-Lih Chang</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32243270</idno><idno type="pmid">32243270</idno><idno type="doi">10.1097/JCMA.0000000000000318</idno><idno type="pmc">PMC7176266</idno><idno type="wicri:Area/Main/Corpus">001A33</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential therapeutic agents against COVID-19: What we know so far.</title><author><name sortKey="Lu, Chih Chia" sort="Lu, Chih Chia" uniqKey="Lu C" first="Chih-Chia" last="Lu">Chih-Chia Lu</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Mei Yu" sort="Chen, Mei Yu" uniqKey="Chen M" first="Mei-Yu" last="Chen">Mei-Yu Chen</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Wan Shin" sort="Lee, Wan Shin" uniqKey="Lee W" first="Wan-Shin" last="Lee">Wan-Shin Lee</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, Yuh Lih" sort="Chang, Yuh Lih" uniqKey="Chang Y" first="Yuh-Lih" last="Chang">Yuh-Lih Chang</name><affiliation><nlm:affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of the Chinese Medical Association : JCMA</title><idno type="eISSN">1728-7731</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Combinations (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Interferon-alpha (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Hydroxychloroquine</term><term>Interferon-alpha</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32243270</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1728-7731</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Journal of the Chinese Medical Association : JCMA</Title><ISOAbbreviation>J Chin Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Potential therapeutic agents against COVID-19: What we know so far.</ArticleTitle><Pagination><MedlinePgn>534-536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCMA.0000000000000318</ELocationID><Abstract><AbstractText>The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chih-Chia</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Yu</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wan-Shin</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yuh-Lih</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Chin Med Assoc</MedlineTA><NlmUniqueID>101174817</NlmUniqueID><ISSNLinking>1726-4901</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32243270</ArticleId><ArticleId IdType="doi">10.1097/JCMA.0000000000000318</ArticleId><ArticleId IdType="pmc">PMC7176266</ArticleId><ArticleId IdType="pii">02118582-202006000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Situation updates on March 26, 2020. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=81b94e61_2. Accessed March 27, 2020.</Citation></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74.</Citation></Reference><Reference><Citation>Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769–802.</Citation></Reference><Reference><Citation>Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252–6.</Citation></Reference><Reference><Citation>Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015;212:1904–13.</Citation></Reference><Reference><Citation>Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 2016;21:455–9.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020. Doi:10.1056/NEJMoa2001282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2001282</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AJ, Won JJ, Graham RL, Dinnon KH, Sims AC, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 2019. Doi: 10.1016/j.antiviral.2019.104541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71.</Citation></Reference><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–36.</Citation></Reference><Reference><Citation>Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981–6.</Citation></Reference><Reference><Citation>Qingxian C, Minghui Y, Dongjing L, Jun C, Dan S, Junxia X, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020. Available at https://doi.org/10.1016/j.eng.2020.03.007. Accessed March 27, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 2018;14:1435–55.</Citation></Reference><Reference><Citation>Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020. Doi: 10.1038/s41421-020-0156-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0156-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020. Doi: 10.1016/j.ijantimicag.2020.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId></ArticleIdList></Reference><Reference><Citation>Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 2007;282:15319–23.</Citation></Reference><Reference><Citation>Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004;189:1164–7.</Citation></Reference><Reference><Citation>Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10:317–9.</Citation></Reference><Reference><Citation>Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013;67:606–16.</Citation></Reference><Reference><Citation>Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014;95Pt 3571–7.</Citation></Reference><Reference><Citation>Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004;72:4410–5.</Citation></Reference><Reference><Citation>Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013;94Pt 122679–90.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.</Citation></Reference><Reference><Citation>Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609–32.</Citation></Reference><Reference><Citation>Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv2020.20200300026</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001A33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32243270
|texte= Potential therapeutic agents against COVID-19: What we know so far.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32243270" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |